Clustering drug-drug interaction networks with energy model layouts: community analysis and drug repurposing

Analyzing drug-drug interactions may unravel previously unknown drug action patterns, leading to the development of new drug discovery tools. We present a new approach to analyzing drug-drug interaction networks, based on clustering and topological community detection techniques that are specific to complex network science. Our methodology uncovers functional drug categories along with the intricate relationships between them. Using modularity-based and energy-model layout community detection algorithms, we link the network clusters to 9 relevant pharmacological properties. Out of the 1141 drugs from the DrugBank 4.1 database, our extensive literature survey and cross-checking with other databases such as Drugs.com, RxList, and DrugBank 4.3 confirm the predicted properties for 85% of the drugs. As such, we argue that network analysis offers a high-level grasp on a wide area of pharmacological aspects, indicating possible unaccounted interactions and missing pharmacological properties that can lead to drug repositioning for the 15% drugs which seem to be inconsistent with the predicted property. Also, by using network centralities, we can rank drugs according to their interaction potential for both simple and complex multi-pathology therapies. Moreover, our clustering approach can be extended for applications such as analyzing drug-target interactions or phenotyping patients in personalized medicine applications.

[1]  A. Graul,et al.  The year's new drugs & biologics, 2013: Part I. , 2014, Drugs of today.

[2]  Ruth Nussinov,et al.  Structure and dynamics of molecular networks: A novel paradigm of drug discovery. A comprehensive review , 2012, Pharmacology & therapeutics.

[3]  F. Pammolli,et al.  The productivity crisis in pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.

[4]  Mircea Vladutiu,et al.  Network Fidelity: A Metric to Quantify the Similarity and Realism of Complex Networks , 2013, 2013 International Conference on Cloud and Green Computing.

[5]  B. Munos Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.

[6]  J. Zeldis,et al.  Thalidomide as a novel therapeutic agent: new uses for an old product. , 2005, Drug discovery today.

[7]  Kristen Fowler,et al.  Hormone Replacement Therapy in Women with Epilepsy: A Randomized, Double‐Blind, Placebo‐Controlled Study , 2006, Epilepsia.

[8]  M. Jacomy,et al.  ForceAtlas2, a Continuous Graph Layout Algorithm for Handy Network Visualization Designed for the Gephi Software , 2014, PloS one.

[9]  Daniel M. Green,et al.  The Central and Peripheral Nervous Systems , 1989 .

[10]  Louise Poissant Part I , 1996, Leonardo.

[11]  Jochen L. Leidner,et al.  Computational drug repositioning based on side-effects mined from social media , 2016, PeerJ Comput. Sci..

[12]  S. Sleigh,et al.  Repurposing Strategies for Therapeutics , 2010, Pharmaceutical Medicine.

[13]  C. Woolley,et al.  Acute inhibition of neurosteroid estrogen synthesis suppresses status epilepticus in an animal model , 2016, eLife.

[14]  Sarah Baxendale,et al.  Identification of compounds with anti-convulsant properties in a zebrafish model of epileptic seizures , 2012, Disease Models & Mechanisms.

[15]  Carole E Shardlow,et al.  Utilizing Drug-Drug Interaction Prediction Tools during Drug Development: Enhanced Decision Making Based on Clinical Risk , 2011, Drug Metabolism and Disposition.

[16]  Rong Wang,et al.  Drug Repurposing Based on Drug–Drug Interaction , 2015, Chemical biology & drug design.

[17]  Jen‐Shi Chen,et al.  Cisplatin-induced acute hyponatremia leading to a seizure and coma: a case report. , 2011, Chang Gung medical journal.

[18]  N. Bhattacharyya,et al.  Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. , 2012, Blood.

[19]  E. Cruces,et al.  The year's new drugs & biologics, 2014: Part I. , 2015, Drugs of today.

[20]  Khader Shameer,et al.  Computational and experimental advances in drug repositioning for accelerated therapeutic stratification. , 2015, Current topics in medicinal chemistry.

[21]  Albert-László Barabási,et al.  Endophenotype Network Models: Common Core of Complex Diseases , 2016, Scientific Reports.

[22]  S. Theodoridou,et al.  Laboratory Investigation of Platelet Function in Patients with Thalassaemia , 2014, Acta Haematologica.

[23]  Thomas M Polasek,et al.  Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment. , 2011, British journal of clinical pharmacology.

[24]  Paul R Cohen,et al.  DARPA's Big Mechanism program , 2015, Physical biology.

[25]  Mathieu Bastian,et al.  Gephi: An Open Source Software for Exploring and Manipulating Networks , 2009, ICWSM.

[26]  R. Karl Rethemeyer,et al.  Network analysis , 2011 .

[27]  Mark E. J. Newman,et al.  The Structure and Function of Complex Networks , 2003, SIAM Rev..

[28]  R. Altman,et al.  Data-Driven Prediction of Drug Effects and Interactions , 2012, Science Translational Medicine.

[29]  Hongkang Mei,et al.  Systematic Prediction of Pharmacodynamic Drug-Drug Interactions through Protein-Protein-Interaction Network , 2013, PLoS Comput. Biol..

[30]  M. Valentovic,et al.  Impact of Insulin or Tolbutamide Treatment on 14C-Arachidonic Acid Conversion to Prostacyclin and/or Thromboxane in Lungs, Aortas, and Platelets of Streptozotocin-induced Diabetic Rats , 1983, Diabetes.

[31]  Pilar Gutiérrez Navarro,et al.  Penicillin degradation catalysed by Zn(II) ions in methanol. , 2003, International journal of biological macromolecules.

[32]  Susumu Goto,et al.  Network-Based Analysis and Characterization of Adverse Drug-Drug Interactions , 2011, J. Chem. Inf. Model..

[33]  Weida Tong,et al.  In silico drug repositioning: what we need to know. , 2013, Drug discovery today.

[34]  Kay-Tee Khaw,et al.  Dietary Potassium and Stroke-Associated Mortality - A 12 Year Prospective Population Based Study , 1986 .

[35]  Monica Milani,et al.  Myasthenia gravis: past, present, and future. , 2006, The Journal of clinical investigation.

[36]  Bence Bolgár,et al.  Drug repositioning for treatment of movement disorders: from serendipity to rational discovery strategies. , 2013, Current topics in medicinal chemistry.

[37]  M E J Newman,et al.  Community structure in social and biological networks , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  M. Dickson,et al.  The cost of new drug discovery and development. , 2004, Discovery medicine.

[39]  Liliane Mouawad,et al.  vSDC: a method to improve early recognition in virtual screening when limited experimental resources are available , 2016, Journal of Cheminformatics.

[40]  O Epstein,et al.  Platelet aggregation and thromboxane A2 release in primary biliary cirrhosis and effect of D-penicillamine treatment. , 1988, Prostaglandins, leukotrienes, and essential fatty acids.

[41]  Richard Svensson,et al.  In Vitro and In Silico Strategies to Identify OATP1B1 Inhibitors and Predict Clinical Drug–Drug Interactions , 2011, Pharmaceutical Research.

[42]  Andreas Noack,et al.  An Energy Model for Visual Graph Clustering , 2003, GD.

[43]  A. Shaughnessy Old drugs, new tricks , 2011, BMJ : British Medical Journal.

[44]  King C. Lee,et al.  Potentiation of the pressor response to stress by tolbutamide in dogs , 1993, Integrative physiological and behavioral science : the official journal of the Pavlovian Society.

[45]  John Newsom-Davis,et al.  A randomized double‐blind trial of prednisolone alone or with azathioprine in myasthenia gravis , 1998, Neurology.

[46]  Zhiyong Lu,et al.  A survey of current trends in computational drug repositioning , 2016, Briefings Bioinform..

[47]  D. C. Henckel,et al.  Case report. , 1995, Journal.

[48]  G. Zlokarnik,et al.  In silico prediction of drug safety: despite progress there is abundant room for improvement. , 2004, Drug discovery today. Technologies.

[49]  E. Chautard,et al.  Interaction networks: from protein functions to drug discovery. A review. , 2009, Pathologie-biologie.

[50]  R P Carlson,et al.  The antiinflammatory action of guanabenz is mediated through 5-lipoxygenase and cyclooxygenase inhibition. , 1987, European journal of pharmacology.

[51]  L. Lewis,et al.  Drug-drug interactions: is there an optimal way to study them? , 2010, British journal of clinical pharmacology.

[52]  David S. Wishart,et al.  DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..

[53]  D. Holdstock Past, present--and future? , 2005, Medicine, conflict, and survival.

[54]  Tudor I. Oprea,et al.  Impact of similarity threshold on the topology of molecular similarity networks and clustering outcomes , 2016, Journal of Cheminformatics.

[55]  M. J. van den Bent,et al.  Cisplatin-induced encephalopathy and seizures. , 2003, Anti-cancer drugs.

[56]  Andreas Noack,et al.  Modularity clustering is force-directed layout , 2008, Physical review. E, Statistical, nonlinear, and soft matter physics.

[57]  Xue-Qing Chen,et al.  Discovery pharmaceutics—Challenges and opportunities , 2006, The AAPS Journal.

[58]  M. Udrescu,et al.  Evaluation of patients diagnosed with essential arterial hypertension through network analysis , 2016, Irish Journal of Medical Science (1971 -).

[59]  K Kawaguchi,et al.  Tolbutamide effect on cultured human endothelial cells with special reference to platelet aggregation. , 1983, The Tohoku journal of experimental medicine.

[60]  D. Dréau,et al.  Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease. , 2004, Molecular cancer therapeutics.

[61]  Edward M. Reingold,et al.  Graph drawing by force‐directed placement , 1991, Softw. Pract. Exp..

[62]  Guanrong Chen,et al.  Complex networks: small-world, scale-free and beyond , 2003 .

[63]  Christian Bauckhage,et al.  Network growth and the spectral evolution model , 2010, CIKM.

[64]  M Hirohashi,et al.  Pharmacological studies with the alpha 2-adrenoceptor antagonist midaglizole. Part II: Central and peripheral nervous systems. , 1991, Arzneimittel-Forschung.

[65]  Mihai Udrescu,et al.  Data Analysis for Patients with Sleep Apnea Syndrome: A Complex Network Approach , 2014, SOFA.